Trials / Completed
CompletedNCT00959816
A Study to Investigate the Process by Which ABT-614 is Absorbed, Distributed, Metabolized and Eliminated in Humans
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Abbott · Industry
- Sex
- Male
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Accepted
Summary
The objective of this study is to determine the amount of ABT-614 in the cerebral spinal fluid and blood after administration of a single dose and after administration of daily doses for 14 days in healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-614 | Single dose administered on Study Day 1 in Part 1, daily dose administered on Study Days 1-14 in Part 2. |
Timeline
- Start date
- 2009-08-01
- Primary completion
- 2009-08-01
- First posted
- 2009-08-17
- Last updated
- 2010-11-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00959816. Inclusion in this directory is not an endorsement.